There is a growing paradox in life sciences commercialization: more data and more research than ever, yet many critical decisions still rely on static decks, siloed databases, and one time studies that go stale almost immediately. Commercial, medical, and market access teams are working harder than ever—often with tools that were never designed for the pace and complexity of today’s markets.
Most commercial life sciences organizations have invested heavily in data. They have lakehouses, harmonized data feeds, and dashboard environments like Power BI, Tableau, and Snowflake that teams rely on daily. These tools already carry semantic models: metric definitions, schema relationships, and governed sources. The analytics infrastructure is real. Yet when they try to build AI on top of it, they hit the same wall: the AI doesn’t understand their business.
Market access teams routinely make high-stakes decisions with incomplete information and compressed timelines. Primary market research remains the gold standard, but in-depth interviews with payers are expensive, logistically complex, and difficult to repeat iteratively as strategy and data evolves. The result is that value messaging frameworks, Target Product Profile (TPP) assumptions, and pricing strategies often have limited payer testing before they meet real payers.